Pfizers Inc., FRESENIUS KABI USA and Cipla are Dominating the Global Lyophilized Injectable Drugs Market in 2021

Global Lyophilized Injectable Drugs Market is expected to grow with the CAGR of 6.2% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-lyophilized-injectable-drugs-market

The global lyophilized injectable drugs market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global lyophilized injectable drugs market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In July 2020, Jubilant Pharma Limited announced that it had received the Drug Controller General of India (DCGI) approval to manufacture and market antiviral drug Remdesivir for 100 mg/vial (lyophilized injection) for emergency use in India for the COVID-19 patients. This approval received by the company has increased its sales and revenue in future.

Pfizers Inc., is dominating player in global lyophilized injectable drugs market. The other key players existing in the market includes Affy Pharma Pvt Ltd., Genex Pharma, AuroMedics Pharma LLC Pharma LLC (a subsidiary of Aurobindo Pharma), Astellas Pharma US, Inc. (a subsidiary of Astellas Pharma Inc.), Aristopharma Ltd., Viatris Inc., Gilead Sciences, Inc., Cirondrugs, Amneal Pharmaceuticals LLC, Jubilant Generics Limited – A Jubilant Pharma Company, Novartis AG, Otsuka America Pharmaceutical, Inc, Zydus Cadila, Cipla Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Fresenius Kabi USA (a subsidiary of Fresenius Kabi AG), Sanofi, Celon Laboratories Pvt. Ltd. and Baxter among others.

Lyophilized Injectable Drugs Market

Pfizer Inc.

Pfizer Inc. is headquartered in New York, U.S. and was founded in 1849. The company is focused on providing standard for quality, safety and value in the discovery, development and manufacturing of health care products including innovative medicines and vaccines.

For instance,

  • In November 2019, Pfizer, Inc. announced that its division, named Upjohn is combined with Mylan N.V. and formed a new company named Viatris, Inc. This combination of the company's business division with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market.

The company has wide global presence across the world as North America, Europe, Asia-Pacific, South America, and Middle East and Africa with its various subsidiaries such as Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V. (Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A. (Dominican Republic) and Pfizer Egypt S.A.E.(Egypt) among others.

Fresenius Kabi USA (a subsidiary of Fresenius Kabi AG)

Fresenius Kabi USA (a subsidiary of Fresenius Kabi AG) is headquartered in Illinois, U.S. and was founded in year 1912. The company is engaged in offering lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company offers a variety of product categories such as pharmaceuticals and medical devices among which the market focused category is pharmaceutical.

For instance,

  • In January 2020, Fresenius Kabi USA announced that it had introduced Bortezomib for Injection is available as a single dose vial containing 3.5 mg of lyophilized powder in the U.S. This availability of the drug in the region has increased its demand and sales in the market, leading to increased revenue in the future.

The company has wide presence in U.S.

Cipla Inc.

Cipla Inc. is headquartered in Mumbai, India and was founded in 1935. The company is engaged in offering advanced pharmaceutical products to meet the needs of people across the globe.  The company has several business segment such as pharmaceuticals and new ventures among which the market focused segment is pharmaceuticals. Along with this, the company offers many product categories such as cipla generics and API. The market focused category is cipla generics.

For instance,

  • In June 2020, Cipla Inc. announced that it had launched the drug named Remdesivir under its brand name CIPREMI for the COVID-19 patients. This product launched by the company during the COVID-19 pandemic has increased its credibility in the market.

The company has wide global presence across the world as North America, Europe, Asia-Pacific, South America, and Middle East and Africa with its various subsidiaries such as Cipla BioTec Limited (India), Jay Precision Pharmaceuticals Private Limited (India), Cipla Medpro South Africa (Pty) Limited (South Africa), Cipla Holding B.V. (Netherlands) and Cape to Cairo Exports Proprietary Limited (South Africa) among others.